Orwell premium
24 July 2018

The drug company is following Pfizer’s lead and floating its animal-health business. Investors are clamoring for the steady growth that rising pet spending brings, which could value the unit at $20 bln. This opportunistic move is just the prescription to boost Lilly’s returns.